Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)

Diabetes, Obesity and Metabolism

Volumn 15, Issue 11, 2013, Pages 1000-1007

  Pinget, M ^a   Goldenberg, R ^b   Niemoeller, E ^c   Muehlen Bartmer, I ^c   Guo, H ^d   Aronson, R ^b  

^a HUS   (France)

^b LMC DIABETES AND ENDOCRINOLOGY   (Canada)

^c Process Development Biotechnology   (Germany)

^d BDM Consulting   (United States)

Author keywords

Glycaemic control; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO;

ACUTE HEART INFARCTION; ALLERGIC CONJUNCTIVITIS; ANAPHYLAXIS; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; VOMITING;

GLYCAEMIC CONTROL; TYPE 2 DIABETES;

AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; MALE; METFORMIN; MIDDLE AGED; PATIENT DROPOUTS; PEPTIDES; RECEPTORS, GLUCAGON; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 84885331631     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12121     Document Type: Article

References (21)

1. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
3. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
4. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011; 33: 511-527.
5. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011; 27: 528-542.
6. Christensen M, Knop FK, Vilsboll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011; 20: 549-557.
7. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diab Med 2010; 27: 1024-1032.
8. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010; 164: 58-64.
9. Ratner R, Hanefeld M, Shamanna P et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea±metformin (GetGoal-S) [Abstract]. Diabetologia 2011; 54(Suppl. 1): A785.
10. Seino Y, Min KW, Niemoeller E, Takami A, EFC GetGoal-L-Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012; 14: 910-917.
11. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evidence 2011; 6: 67-79.
12. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405.
13. Bolli G, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Hanefeld M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1) [Abstract]. Diabetologia 2011; 54(Suppl. 1): A784.
14. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012; 35: 1225-1231.
15. Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013; 36: 2543-2550.
16. Riddle MC, Aronson R, Home P et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013; 36: 2489-2496.
17. Riddle MC, Forst T, Aronson R et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013; 36: 2497-2503.
18. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
19. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001; 121: 13-18.
20. Becker RHA, Stechl J, Kapitza C, Msihid J. Augmentation of 1st-phase insulin release with lixisenatide in non-diabetic subjects. Diabetes 2012; 61: A296 (Abstract 1149-P).
21. Rosenstock J, Raccah D, Koranyi L et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; DOI: DC12-2709.R2701.